Complete Response Letters
Zhejiang Novus Pharmaceuticals Co. Ltd.: Vancomycin Hydrochloride
What FDA's Complete Response Letters to the company say, in the letters' own words.
Complete Response Letter, Aug 25, 2021
Drug, and Cosmetic Act for Vancomycin Hydrochloride for Injection, 500 mg/vial, 1 gram/vial, 5 gram/vial, and 10 gram/vial.
CRL_NDA210274_20210825:p1:s12Complete Response Letter, Nov 27, 2020
Pharmaceuticals Co., Ltd. FEI: 3013567704 manufacturing facility at Zhejiang, China, for this application, our field investigator observed objectionable conditions at the facility and conveyed that information to the representative of the facility at the close of the inspection.
CRL_NDA210274_20201127:p1:s19Satisfactory resolution of the remaining objectionable conditions, and verification by the FDA, is required before this application may be approved.
CRL_NDA210274_20201127:p1:s20In any resubmission of this application, please submit revised draft carton and container labeling that contains the following revisions:
CRL_NDA210274_20201127:p1:s44Complete Response Letter, Jun 15, 2018
Please note the amendments dated May 11, 2018 and May 25, 2018, were not reviewed during this review cycle.
CRL_NDA210274_20180615:p1:s16More Complete Response Letters
Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.